Zerbor/iStock via Getty Images Rhythm Pharmaceuticals (NASDAQ:RYTM) said it plans to acquire the global licensing rights from South Korea's LG Chem for drug candidate LB54640, which is being developed for the treatment of obesity. Under the deal, Rhythm will pay LG Chem $40M in cash and $20M in Rhythm equity at closing, plus $40M in cash 18 months after the closing.

Zerbor/iStock通过Getty Images Rhym Pharmaceuticals（NASDAQ:RYTM）表示，计划从韩国LG Chem获得候选药物LB54640的全球许可权，该药物正在开发用于治疗肥胖症。根据该协议，Rhythm将在交割时向LG Chem支付4000万美元现金和2000万美元Rhythm股权，并在交割后18个月支付4000万美元现金。

LG Chem could also receive up to $205M if certain milestones are achieved, plus royalties on product sales, according to a statement. Rhythm said the drug, an orally administered MC4R molecule, is currently in Phase 2 testing. The company hopes to eventually be able to develop a portfolio of treatments based on the molecule for the treatment of severe obesity and hyperphagia, the medical term for insatiable hunger pangs that can lead to overeating.

据一份声明称，如果达到某些里程碑，LG Chem还可能获得高达2.05亿美元的收入，外加产品销售的版税。节奏说，该药物是一种口服MC4R分子，目前正在进行第二阶段测试。该公司希望最终能够开发一种基于该分子的治疗组合，用于治疗严重肥胖和食欲亢进，这是一种医学术语，用于描述可能导致暴饮暴食的永不满足的饥饿感。

Under the agreement, Rhythm will assume sponsorship of two Phase 2 trials evaluating the drug for weight loss. LB54640 has already received Orphan Drug Designation from the FDA for leptin receptor deficiency and proopiomelanocortin, Rhythm said. Also on Thursday, Rhythm said it had completed screening for enrollment for a Phase 3 study of its drug candidate setmelanotide for the treatment of acquired hypothalamic obesity, with topline data expected in the first half of 2025.

根据协议，Rhythm将赞助两项评估该药物减肥效果的2期临床试验。Rthym表示，LB54640已经因瘦素受体缺乏症和促黑素皮质激素原而被FDA指定为孤儿药。同样在周四，Rhythm表示，它已经完成了候选药物setmelanotide治疗获得性下丘脑肥胖的3期研究的登记筛选，预计2025年上半年将有topline数据。

More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Pfizer hits new 52-week low after weight loss setback Rhythm Pharmaceuticals Q3 2023 Earnings Preview .

更多关于节奏制药节奏制药：减肥的主要催化剂专业节奏制药公司（RYTM）2023年第三季度收益通话记录节奏制药公司2023年第三季度-结果-收益通话报告辉瑞在减肥受挫后创下52周新低节奏制药公司2023年第三季度收益预览。